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Abstract
Background: Human Papilloma Virus (HPV) vaccine has undergone successful trials and has
recently been approved for use for the primary prevention of cervical cancer. The aim of this study
was to determine knowledge and attitudes towards HPV vaccination.
Methods: Semi-structured interview and questionnaire delivered in a street survey. Standardised
HPV-related statements used to measure HPV knowledge and attitudes to vaccination. The setting
was three different areas of Birmingham, to target a mix of social class and ethnicity. The sample
population was composed of 16–54 year olds.
Results: A total of 420 participants were recruited. Poor knowledge of HPV and its links with
cervical cancer were observed. 81% had a knowledge score of zero. Knowledge about HPV was
associated with different ethnic group and socio-economic group. The majority (88%) of
participants were in favour of vaccination, with 83.6% indicating that they would allow a child under
their care to be vaccinated.
Conclusion: Initial responses to the proposed HPV vaccination within the UK public are
favourable. However, knowledge levels are poor and media and health professional promotion are
required to raise awareness.
Background
Since the 1970's it has been known that one of the causes
of cervical cancer is through infection with Human Papil-
loma Virus (HPV) [1] subtypes of HPV causing malignant
transformation of the cervical epithelium [1,2]. This
breakthrough led to the possibility that some cervical can-
cers could be preventable by vaccination [1,2]. There are
approximately one hundred different genotypes of HPV.
[3] Forty of these types infect the genitalia, and fifteen put
women at a high risk of cervical cancer [3,4]. In the UK
and many other countries, HPV-16 and 18 are the most
common subtypes associated with cervical carcinoma and
are believed to be implicated in the aetiology of 70% of
malignancies [2,3].
Published: 23 October 2008
BMC Public Health 2008, 8:368 doi:10.1186/1471-2458-8-368
Received: 16 January 2008
Accepted: 23 October 2008
This article is available from: http://www.biomedcentral.com/1471-2458/8/368
© 2008 Walsh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Public Health 2008, 8:368 http://www.biomedcentral.com/1471-2458/8/368An HPV vaccine has been developed by two separate drug
companies: Merck, which produces Gardasil, and Glaxo-
SmithKline, which produces Cervarix [5]. Both drugs have
undergone phase III trials, and were approved for use in
the USA in 2006, the Merck vaccine was also approved for
use in the UK in 2006 [1,6-10]. To maximise effectiveness,
the vaccine needs to be given to girls before they are sexu-
ally active [11]. Initial discussions for a UK vaccination
programme suggested targeting girls aged 10–12 years
[12]. On 26th October 2007, the Department of Health
(England) announced the Government immunisation
programme would commence in 2009 with HPV vaccina-
tion of girls aged 12–13 years [13,14].
Despite HPV vaccination being a relatively new concept,
there are a number of studies that have discussed the effec-
tiveness of the vaccine and how it works [6-9,15]. How-
ever, relatively few investigations have addressed the
public's support for vaccinating school age children. The
majority of the research that has been undertaken has not
been based in the UK [16-20] and reports parental (espe-
cially maternal) and adolescent attitudes towards HPV
vaccination, rather than the attitudes of the general public
[19-22].
A Finnish study reported 86% of parents and adolescents
approved of the vaccine [19] and over 90% of mothers in
Vietnam were in favour of their daughters receiving the
vaccine although only 1% had previous awareness of the
possibility of vaccination [20]. Such findings are re-
enforced by a recent review of the literature on HPV vac-
cine acceptability which reported that many women had
a poor knowledge about HPV but, nevertheless, most par-
ents are interested in having their children vaccinated
[23].
A Canadian study, published in 2000, assessing public
knowledge reported that only 13% of adolescents had
heard about HPV [24], however a more recent study, con-
ducted 2006–07, reported that 70% of respondents with
female children intended to have their daughters vacci-
nated [25]. A study, in Georgia, undertook 35 focus
groups with stratification by gender, race and location.
Knowledge, attitude and beliefs about HPV were explored.
Low knowledge and the association of the vaccine with
STD were concluded to be barriers to future acceptance of
the vaccine [26].
The relatively small number of UK based studies under-
taken to date also tend to report that people generally
know little about HPV, but after the provision of informa-
tion, most support the introduction of the vaccine [27-
30]. A recent survey of British women aged 16–97 used an
open question to elicit the causes of cervical cancer; only
2.5% mentioned HPV and 7% mentioned an unspecified
sexually transmitted virus/infection [28]. However, the
majority of parents of 11–12 year old school children
state that they would allow their child to be vaccinated
[27,30] and only a minority express concern that it may
encourage unsafe sexual behaviour [27,30]. This latter
issue has appeared in national newspapers, with one
paper leading with the headline "NHS giving out 'promis-
cuity jab' by the backdoor" [31].
In summary the literature published to date shows low
levels of public knowledge about HPV and its links to cer-
vical cancer. However, the majority of studies also show
that people are generally in favour of vaccination.
This study aimed to determine public awareness of, and
attitudes towards, HPV vaccination in three urban areas of
Birmingham. Secondary aims were to determine the effect
of social class and ethnicity on attitudes towards the pro-
posed vaccine. A better understanding of factors that may
be associated with low knowledge or negative attitudes to
screening being important to inform the targeting of
future awareness campaigns.
Methods
Settings/Study Population
Participants were recruited from the Birmingham area of
the United Kingdom during period April-May 2007. The
Birmingham conurbation has a 66% White British popu-
lation, compared with a national average of 87% [32].
Ethnic minority groups (excluding White Irish) make up
29.6% of the population compared with the national
average of 7.9%. These ethnic groups (in order of size)
comprise Pakistani, Indian, Black Caribbean, mixed races,
Bangladeshi, and smaller groups such as Chinese and
Black Africans.
To ensure a range of participants were recruited, data col-
lection was conducted in three areas of Birmingham
(Northfield – predominantly White, British, Ladywood –
relatively high proportion of ethnic minorities, Sutton
Coldfield – population generally of a higher social class
compared to the other two areas), which were purposively
chosen to reflect the diversity of social class and ethnicity
across the city.
Data collection
This cross-sectional survey was conducted as a street sur-
vey. Members of the public were recruited to participate in
a semi-structured interview using flash cards as prompts
for the collection of categorical data. The main street of
each area was used to ensure access to a large and varied
selection of people. All interviews were conducted by four
medical students. Practice interviews were conducted
before the commencement of data collection to ensurePage 2 of 9
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ner.
Purposive sampling was used to ensure the inclusion of
sufficient subjects in each sub-group of interest (age, gen-
der, socio-economic group, ethnicity). The composition
of the study sample was predetermined and aimed to
recruit adults (aged 16–54 years) in the following propor-
tions: white 70%, ethnic minorities 30%; three geograph-
ical locations: 33.3% each; non manual workers (social
classes 1-3N) 50%, manual workers (social classes 3M-5)
50%; male 50%, female 50%; age bands, 16–24, 25–34,
35–55, 45–54, 25% each).
Balanced groups were obtained by pre-determining the
number of people required in each sub-group of interest.
After a short introduction about the study, potential par-
ticipants were first asked their age, then ethnicity and
socio-economic group to determine eligibility. If suffi-
cient participants had been recruited to the relevant sub-
group, potential participants were thanked for their time
and told that sufficient people in this sub-group had
already been recruited. Recruitment continued in each of
the three geographical areas until sufficient people had
been recruited into each strata. Information on the recruit-
ment rate and the characteristics of non-participants were
not collected.
Social class was assessed using the Registrar General's
Social Scale [33] which has six groups (1: Professional e.g.
accountant, Doctor, Lawyer; 2: Intermediate e.g. manager,
school teacher, nurse; 3N: Skilled Non-manual e.g. Cleri-
cal worker, secretary and shop assistant; 3M: Skilled Man-
ual e.g. Bus driver, Coal-face worker, Carpenter; 4: Semi-
skilled manual e.g. Agricultural worker, Bus conductor,
Postman; 5: Unskilled manual e.g. Labourer, Cleaner,
Dock worker). Ethnicity was assessed using the criteria for
the UK 2001 Census [34].
A sample size of 383 was pre-specified as being sufficient
to determine the proportion of people with a knowledge
score of less than 2 with 5% precision, 90% power and
95% confidence [35].
Measurement and Analysis
Data collected were entered into SPSS V 14.0. Data entry
errors were resolved by reference to data collection sheets.
Questionnaire administration commenced with socio-
demographic questions, followed by an assessment of
HPV knowledge. Therefore, for each respondent, a knowl-
edge score was calculated from six HPV related questions.
One point was allocated for each positive ("yes") answer
resulting in a score from zero to six [0 (no knowledge) to
6 (high knowledge)]. If the respondent answered "No" to
the first of these questions ("Have you heard of HPV?"),
then the remaining HPV knowledge questions were not
asked. For the purposes of modelling, the knowledge
score was reduced to a binary variable (no knowledge:
knowledge score = 0 vs. some knowledge: knowledge
score >0).
The six questions asked comprised:
1) Have you heard about Human Papilloma Virus?
2) Did you know the Human Papilloma Virus can be
transmitted through sexual intercourse?
3) Have you heard about the HPV vaccination?
4) Did you know it is a vaccination which protects women
against cervical cancer?
5) Did you know that the government is considering
offering HPV vaccination to school girls aged 10–12?
6) Did you know a lot of women have already acquired
one or more HPV type(s) covered by the vaccine?
Subsequent to the provision of standardised information
(information provided to all participants, irrespective of
HPV knowledge score) relating to HPV, attitudes to HPV
vaccination were assessed using the question: "Do you
think that the introduction of HPV vaccination is a good idea?"
A Likert scale ranging from strongly agree (score: 1) to
strongly disagree (score: 5) was used. For the purposes of
modelling, the attitude score was reduced to a binary var-
iable (negative attitude: no opinion, disagree and strongly
disagree, vs. positive attitude: agree and strongly agree).
The interview ended with some questions relating to how
much people were prepared to pay for vaccination and
whether boys should also be vaccinated.
To facilitate modelling, independent variables were
dichotomised to: manual (3M-5) vs. non-manual (1-3N),
older (age 45+) vs. younger (age <45), white vs. non-white
(all ethnic groups other than white British).
A parent was defined as anyone with children regardless
of age of the child. Parents were asked to imagine when
their child was the target age (10–12 years) and to answer
the questions relating to attitudes to vaccination accord-
ingly.
Data were not normally distributed. The Mann Whitney U
test (gender, social class, ethnicity, parenthood) and
Kruskal-Wallis test (age groups, areas) were used to test for
differences between groups in knowledge and attitude
scores. Mean knowledge scores are reported in the text, allPage 3 of 9
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logistic regression (forward stepwise method) was con-
ducted, using SPPS v14, to explore the effect of variables
demonstrated to be significantly associated with the out-
comes of interest (knowledge, attitude) in the univariate
analyses.
Ethical approval for this study was provided by South Bir-
mingham Research Ethics Committee in November 2006
(ref: S/2006/113).
Results
One hundred and forty people in each of the three loca-
tions were recruited, generating a total sample of 420
(Table 1). Of the 420 people, 315 (75%) were white and
105 (25%) ethnic minorities. The non-manual group
(social classes I – IIIM) comprised 241 (57.4%) people
with 179 (42.6%) in the manual (social classes IV – V).
159 (37.9%) participants were male and 261(62.1%)
female. There were 20%–30% participants in (each of the
four age group bands). Fifty-nine per cent of the 420 par-
ticipants were parents.
Knowledge Score
Three hundred and forty (81%, 95% CI = 76.9% to
84.6%) of the study participants had a knowledge score of
0 (mean = 0.51, SD = 1.33, median = 0). Only 25 (5.9%)
participants had a score of 4 or more. The proportion of
participants with a Knowledge scores of 0–6 varied by
subgroup (ethnicity, gender, social class and age) (Table
2).
Significant differences in knowledge scores were observed
between ethnic groups (scores >0: 23% of white and 8.3%
of non-white category); social class (scores >0: 30.1% of
non-manual and 9.8% of manual category); with increas-
ing age (scores >0: 16.24 = 12.7%, 25–34 = 19.8%, 35–44
= 17.5%, 45–54 = 28%), and by gender (scores >0: males
Table 1: Characteristics of participants
N %
Area
Ladywood 140 33.3
Northfield 140 33.3
Sutton Coldfield 140 33.3
Age Group
16–24 110 26.2
25–34 91 21.7
35–44 126 30.0
45–54 93 22.1
Gender
Male 159 37.9
Female 261 62.1
Ethnicity
White British and Irish 305 72.6
Mixed 13 3.1
Asian (Indian, Pakistani, Bangladeshi or other) 54 12.9
Black (Black African, Black Caribbean or other) 37 8.8
Other (including Chinese) 11 2.6
Social Class
I 9 2.1
II 67 16.0
IIIN 109 26.0
IIIM 56 13.3
IV 61 14.5
V 118 28.1
Parents
Yes 248 59.0
No 172 41.0Page 4 of 9
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knowledge scores were revealed between parents and
those who were not parents (mean scores = 0.58 and 0.40
respectively) (p = 0.285) or between the three geographi-
cal areas surveyed (p = 0.19).
Logistic regression modelling explored the effect of gen-
der, age group, ethnic group and social class on knowl-
edge scores (any knowledge vs. no knowledge). Predictors
of having no knowledge were non white ethnicity
(adjusted odd ratio = 2.96, 95%CI 1.44 to 6.10) and being
a manual worker (OR = 4.10, 95%CI 2.39 to 7.06). Older
age (45+ years) resulted in a decreased probability of no
knowledge (OR = 0.32, 95%CI 0.30 to 0.96). After includ-
ing ethnicity, social class and age band in the model, gen-
der was no longer a significant factor.
Attitude towards HPV Vaccination
Three hundred and seventy (88.1%, 95% CI 84.4% to
90.9%) participants agreed or strongly agreed with HPV
vaccination, 6% had no opinion and 6% disagreed or
strongly disagreed. The median score was 2.0 (1 = Strongly
Agree, 5 = Strongly Disagree); participants tending to
report that they agreed with vaccination. The mean
response for attitude for the white ethnic group was 1.88
(Table 3) whereas, the mean response for the non-white
group was 2.13; the white ethnic group were more
inclined to agree with vaccination. This association was
significant at the 5% confidence level by the Mann-Whit-
ney U test (p = 0.006). (Table 3) Attitude did not differ sig-
nificantly by social class, gender, parental status or
between the three geographical areas surveyed.
Logistic regression modelling explored the effect of age
group and ethnicity on attitude (positive attitude to vacci-
nation vs. other). The only significant predictor of not
having a positive attitude to vaccination was non- white
ethnicity (odds ratio = 2.62, 95%CI 1.16 to 5.92).
Other data
Participants were asked whether they were parents or not
but this was not associated with either the knowledge
score or attitude response.
A large proportion (70.5%) of the study population
would want the vaccination to be free. The majority
Table 2: Knowledge scores by ethnicity, social class; age and gender
KNOWLEDGE SCORE
0 1 2 3–4 5–6 Mean score SD p-value*
Ethnicity
White N 235 30 13 13 14 0.61 1.416
% 77.0 9.8 4.3 4.3 4.6
Non-White N 105 4 1 2 3 0.26 1.035 0.001
% 91.3 3.5 0.9 1.7 2.6
Social Class
Non-manual (I-IIIN) N 128 22 8 12 15 0.90 1.745
% 69.2 11.9 4.3 6.5 8.1
Manual (IIIM-V) N 212 12 6 3 2 0.20 0.742 <0.001
% 90.2 5.1 2.6 1.3 0.9
Age
16–24 N 96 8 3 2 1 0.25 0.826
% 87.3 7.3 2.7 1.8 0.9
24–34 N 73 9 3 4 2 0.44 1.128
% 80.2 9.9 3.3 4.4 2.2
34–44 N 104 7 4 5 6 0.52 1.390
% 82.5 5.6 3.2 4.0 4.8
44–54 N 67 10 4 4 8 0.86 1.779 0.034
% 72.0 10.8 4.3 4.3 8.6
Gender
Male N 136 12 3 4 4 0.35 1.091
% 85.5 7.5 1.9 2.5 2.5
Female N 204 22 11 11 13 0.61 1.450 0.05
% 78.2 8.4 4.2 4.2 5.0
* derived from Kruskall-Wallis test for age; Mann-Whitney U test for other factorsPage 5 of 9
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group (10–12 years) was acceptable, whereas 34.3% disa-
greed.
The majority of study participants believed that boys
should be vaccinated as well as girls (91.2%).
The majority of participants (83.6%), both parents and
non-parents. reported that they would give consent for
their child to have the vaccination.
Discussion
This study assessed knowledge and attitudes towards HPV
vaccination at a time before the UK Government
announced its plans for a vaccination programme. Partic-
ipants aged 16–54 were recruited from three different
areas of Birmingham. The majority of participants had lit-
tle awareness of HPV or HPV vaccination and 81% had a
knowledge score of zero. Nevertheless, after the provision
of brief HPV related information messages (Table 4), most
(88%) participants were supportive of HPV vaccination.
These findings are in accordance with previous UK-based
studies which have demonstrated that people generally
know little about HPV, but after the provision of informa-
tion, most support the introduction of the vaccine [27-30]
and re-enforce the need for more educational intervention
in order to raise awareness [36].
Although generally low, knowledge scores were higher in
the white ethnic group than in the minority ethnic groups
and in the non-manual worker group compared to the
manual worker group. The white ethnic group were more
in favour of HPV vaccination than the minority ethnic
group. Both the social class groups were willing to accept
HPV vaccination. Stepwise modelling selected social class
in preference to the other explanatory variables in predict-
Table 3: Attitude by ethnicity, social class; age and gender
ATTITUDE
1 2 3 4 5 Mean score SD p-value*
Ethnicity
White N 80 197 15 11 2 1.88 0.71
% 26.2 64.6 4.9 3.6 0.7
Non-White N 21 72 10 10 2 2.13 0.87 0.006
% 18.3 62.6 8.7 8.7 1.7
Social Class
Non-manual (I-IIIN) N 41 123 9 10 2 1.97 0.77
% 22.2 66.5 4.9 5.4 1.1
Manual (IIIM-V) N 60 146 16 11 2 1.93 0.77 0.62
% 25.5 62.1 6.8 4.7 0.9
Age
16–24 N 27 73 7 3 0 1.87 0.64
% 24.5 66.4 6.4 2.7 0.0
24–34 N 26 55 4 6 0 1.89 0.77
% 28.6 60.4 4.4 6.6 0.0
34–44 N 19 88 11 6 2 2.08 0.76
% 15.1 69.8 8.7 4.8 1.6
44–54 N 29 53 3 6 2 1.91 0.89 0.047
% 31.2 57.0 3.2 6.5 2.2
Gender
Male N 38 104 11 3 3 1.92 0.74
% 23.9 65.4 6.9 1.9 1.9
Female N 63 165 14 18 1 1.96 0.78 0.769
% 24.1 63.2 5.4 6.9 0.4
* derived from Kruskall-Wallis test for age; Mann-Whitney U test for other factors.
ATTITUDE:
1 = STRONGLY AGREE.
2 = AGREE.
3 = NO OPINION.
4 = DISAGREE.
5 = STRONGLY DISAGREE.
Attitude assessed by the question: "Do you think that the introduction of HPV vaccination is a good idea?Page 6 of 9
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degree of correlation between ethnicity, social class group
and area of residence and each of these factors may be a
surrogate for educational attainment.
However, a relatively large proportion of participants
(34.3%) reported concern at the proposed target age
group (10–12 years old). Most participants that disagreed
with this target group reported that they felt the age group
was too young. This survey was undertaken at when the
likely age-group for vaccination was believed to be 10–12
years. The recent announcement that the target age group
has been increased to 12–13 years may result in increased
acceptability. This supports the findings of previous stud-
ies in both the USA [37] and UK [38] which have reported
less parental support for vaccination in younger age
groups.
The small group of the public (6%) who expressed no
opinion towards the vaccination could be due to the fact
that they had no or very little knowledge about the vacci-
nation and didn't feel informed enough to form an opin-
ion. Increased awareness and relating to vaccination and
the reasons for vaccinating girls at age 12–13 years may
address this.
The vast majority (83.6%) of participants (parents and
non-parents) would consent for their child to be vacci-
nated. This implies a high uptake of the vaccination
within the UK population, although reported action does
not always reflect actual behaviour.
Limitations of this study include the possibility of sam-
pling bias. As with most cross-sectional surveys, this street
survey was only completed by a self-selected group of
individuals who may not be representative of the general
population. Similarly, the language barrier may have
affected uptake ratio in the ethnic minority population,
however, the vast majority of the people approached were
fluent in English even if it was not their first language. It is
probable that those not confident in written English were
enabled to participate by the use of a semi-structured
interview rather than a postal questionnaire.
Pilot work identified that the initial approach to the pub-
lic was important; initial reactions often being that the
interviewers were attempting to sell a product. Therefore,
in the actual survey, all participants were approached by
medical students who stated that this was a University
research project.
People who failed to take part in the study might differ in
their attitudes towards HPV vaccination. Unfortunately,
due to the nature of the street survey (purposive sam-
pling) refusal rates were not collected and it was not pos-
sible to establish the characteristics of non-participants. It
is probable that those with no knowledge of HPV would
be less inclined to participate. Knowledge of HPV and the
proposed vaccination programme may therefore be over-
estimated and social desirability bias may mean that
reported acceptability of vaccination is over-reported.
This study involved researcher/participant discussion
about a Sexually Transmitted Infection (STI). STI's are a
sensitive subject especially within different cultures.
Questioning people's attitudes towards HPV could be
potentially embarrassing for the participant and may have
deterred honest responses. To minimise the embarrass-
ment experienced by participants a very simple knowl-
edge score comprising only six questions was used; this
may not have been as sensitive as more detailed surveys
[25].
This study supports the findings of previous studies in
respect to the public's knowledge and attitudes to HPV
and the vaccination. The majority of the existing research
has assessed the attitudes and knowledge of adolescents
and their parents, especially mothers [16-18]. This survey
has demonstrated that, in the UK, the attitudes and
knowledge of parents and non-parents are similar and it
therefore may be possible to generalise from studies
focussing on parents to the wider population.
Conclusion
The study confirms that there is still a lack of information
or access to information about HPV and that more needs
to be done to raise awareness of HPV and HPV vaccina-
tion especially amongst the minority ethnic groups and
the lower social classes. Nevertheless, if the vaccination is
introduced it appears that a significant number of people
would be agreeable to vaccination after the provision of
the quite simple messages.
Table 4: HPV related information provided to participants
• Most cervical cancer is caused by HPV infection.
• HPV is a sexually transmitted infection that can affects both males and females.
• The vaccine protects against HPV infection.
• The government is considering introducing the vaccination.
• Like rubella, the HPV vaccination will be a school based vaccination programme and be given to girls between 10 – 12 years.
• Vaccination only effective in people that have not yet been infected with HPV.Page 7 of 9
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cies to play a more active role in publicising, educating
and informing patients on HPV and potential value of
HPV vaccination.
Further work is required to look at the attitudes of health
professionals in the UK towards HPV vaccination.
In conclusion, the success of the newly proposed HPV vac-
cination will depend on public attitudes and acceptance.
This study demonstrates that most people state that they
would accept the vaccination if it were offered, but more
information is needed to increase knowledge. Despite the
general view being positive, many people expressed a wish
to know more about vaccination. Possible side effects,
efficacy, costs and the age group were highlighted as areas
of concern.
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